Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.

This corrects the article DOI: 10.1038/bjc.2017.327.

Correction to: British Journal of Cancer (2018) 118, 156–167; doi: 10.1038/bjc.2017.327; published online 26 September 2017

There was an error in the description of the pharmacodynamics within the ‘Materials and methods’ section of this manuscript, and with the reference cited Printz . The correct description is shown below:

Pharmacodynamics

HA plasma concentrations: The in vivo pharmacologic activity of PEGPH20 was evaluated by measuring plasma concentrations of HA following PEGPH20 administration. Blood samples were collected and analysed at a bioanalytical laboratory (MicroConstants, Inc., San Diego, CA, USA) using a validated assay (Printz ). Plasma samples were enzymatically digested with chondroitinase ABC to hydrolyse different sizes of HA to the smallest HA-disaccharide, followed by derivatization with 4-nitrobenzyl hydroxylamine and analysis using high-performance liquid chromatography and tandem mass spectrometry. Plasma concentrations of HA were determined using reference standards and reported as nanograms of HA-disaccharide per millilitre of plasma. The lower limit of quantification was 42.3 ng ml−1 (normal range, 10–100 ng ml−1, Fraser et al, 1997).

There is no impact on the study results disclosed in the manuscript nor on the conclusions of the study. The results displayed in Figure 1 PEGPH20 Plasma Pharmacokinetics and Pharmacodynamics are consistent with the corrected method as described above.

The original HTML and PDF versions of this manuscript have been corrected, and can be found online and in the print issue.